The BIRC5 (Survivin) gene is located at chromosome 17q in the region that is frequently gained in high risk neuroblastoma. BIRC5 is strongly over expressed in neuroblastoma tumor samples, which correlates to a poor prognosis. We recently 
Introduction BIRC5 (Survivin) is an Inhibitor of Apoptosis Protein (IAP) with a crucial function
in cell cycle and apoptotic signaling. In the intrinsic apoptotic pathway it can bind and inhibit the pro-apoptotic protein DIABLO and it can bind and stabilize XIAP, another IAP. Inhibition of this function of BIRC5 induces apoptosis by activating the intrinsic apoptotic pathway. [1] [2] [3] In addition, BIRC5 can stabilize microtubules in the chromosomal passenger complex during mitosis. Inactivation of BIRC5 can therefore also lead to mitotic catastrophe which activates the intrinsic apoptotic pathway via TP53 and Caspase 2. [3] [4] [5] [6] [7] Genomic aberrations of the BIRC5 locus at 17q occur in several malignancies. BIRC5 is gained in almost all high risk neuroblastoma which is a pediatric tumor that originates from the neural crest derived precursor cells of the sympathetic nervous system. [8] [9] [10] BIRC5 over expression in these tumors strongly correlates to a poor prognosis. BIRC5 knockdown in neuroblastoma causes apoptosis via mitotic catastrophe, suggesting that in these tumor cells the crucial function of BIRC5 is microtubule stabilization.
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In addition to gain of the BIRC5 locus at 17q, only few other aberrations in apoptotic signaling have been reported in neuroblastoma tumors and cell lines. 12, 13 TP53 mutations are rare and many cell line experiments showed that TP53 can be activated to induce apoptosis 14, 15 . Caspase 8 is hypermethylated and thereby inactive in some neuroblastoma resulting in an inactive extrinsic apoptotic pathway. 16 And finally BCL2 is often over expressed in neuroblastoma tumors and has been found to be a target for therapy. 17, 18 Thus, BIRC5 is one of the few drugged targets in the intrinsic apoptotic pathway. This warrants further validation in neuroblastoma since current treatment regimens can only cure 25-35% of high stage neuroblastoma patients and there is a strong need for new targeted therapies. [8] [9] [10] BIRC5 has shown to be a viable therapeutic target 22, 23 In a Phase II trial in melanoma the pre-specified criterion for success was not reached 24 , but in
Non-small-cell-lung-cancer 5% of the patients showed a partial response, and 38%
showed stable disease 25 . YM155 has also induced responses in a phase I trial in patients with non-Hodgkin's Lymphoma or prostate cancer. 23 In this paper we investigated the efficacy of YM155 in 23 neuroblastoma cell lines and 4 neuroblastoma 'Tumor Initiating Cell' (TIC) lines. First, we validated BIRC5 as a therapeutic target by lentiviral shRNA mediated silencing of BIRC5, which resulted in massive apoptosis in all 6 neuroblastoma cell lines tested. Subsequent assays using YM155 induced apoptosis in the majority of 23 tested neuroblastoma cell lines as well. Surprisingly, some cell lines that were sensitive for targeted silencing using BIRC5 shRNA were resistant to YM155. Analysis of mRNA profiles of sensitive and insensitive cell lines identified the multi drug resistance pump ABCB1 (MDR1) [26] [27] [28] , as the best predictor of resistance. Inhibition of ABCB1
with cyclosporine or lentiviral shRNA sensitized the resistant cell lines to YM155 induced apoptosis.
Methods

Cell lines
All cell lines were grown in Dulbecco Modified Eagle Medium (DMEM), supplemented with 10% fetal calf serum, 10 mM L-glutamine, 10 U/ml penicillin/streptomycin, Non
Essential Amino Acids (1x) and 10 μg/ml streptomycin. Cells were maintained at 37 ˚C under 5% CO 2 . For primary references of these cell lines, see Molenaar et al 29 .
The Tumor Initiating Cell (TIC) lines were isolated directly from patient tumor or bone marrow cells and cultured in neural specific stem cell medium (400 ml DMEM glutamax, 133 ml F12 medium, 2% B27, 20ng/ml EGF, 40 ng/ml FGF, 10 U/ml penicillin/streptomycin) as described previously 30 .
Lentiviral shRNA production and transduction
Lentiviral particles were produced in HEK293T cells by cotransfection of lentiviral vector containing the short hairpin RNA (shRNA) with lentiviral packaging plasmids pMD2G, pRRE and pRSV/REV using FuGene HD. Supernatant of the HET293T 
Lentiviral over expression clones
BIRC5 over expression constructs 7 and 10 were produced from a PCR product of BIRC5 (CCDS11755.1: isoform 1) that was obtained from 
RNA extraction and Affymetrix profiling
For profiling total RNA of neuroblastoma cell lines was extracted using Trizol reagent (Invitrogen) according to the manufacturer's protocol. RNA concentration was determined using the NanoDrop ND-1000 and quality was determined using the RNA 6000 Nano assay on the Agilent 2100 Bioanalyzer (Agilent Technologies).
For Affymetrix Microarray analysis, fragmentation of RNA, labeling, hybridization to HG-U133 Plus 2.0 microarrays and scanning was carried out according to the 56 manufacturer's protocol (Affymetrix Inc.). The expression data were normalized with the MAS5.0 algorithm within the GCOS program of Affymetrix. Target intensity was set to 100 (α1=0.04 and α2 0.06). If more than one probe set was available for one gene the probe set with the highest expression and most present calls was selected, considered that the probe set was correctly located on the gene of interest. Mostly this is a probe set at the 3' end. The data were analyzed with the R2 microarray analysis and visualization platform (http://r2.amc.nl).
MTT-assay
Forty-eight hours after treatment with YM155, 10 µl of Thyazolyl blue tetrazolium bromide (MTT, Sigma M2128) was added to the cells. After 4-6 hours of incubation 100 µl of 10% SDS, 0.01 M HCl was added to stop the reaction. The absorbance was measured at 570 nm and 720 nm using a platereader (biotek). The IC50
(concentration drug needed for 50% cell viability reduction) was calculated using concentration vector curves.
Western Blotting
Twenty-four to fourty-eight hours after treatment with YM155 or 48 -72 hours after 
FACS analysis
Seventy-two hours after treatment with YM155 both the attached and the floating cells were fixed with 100% ethanol at -20 ºC. After fixing, the cells were stained with 0.05 mg/ml propidium iodide and 0.05 mg/ml RNAse A in PBS. After 1 hour incubation, DNA content of the nuclei was analyzed using a fluorescence activated cell sorter (Accuri). A total of 10,000 nuclei per sample were counted. The cell cycle distribution and apoptotic sub G1 fraction was determined using Flowjo.
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Crystal Violet
Forty-eight hours after treatment the cells were fixed with 100% ice cold methanol for 10 minutes and stained with Crystal Violet (0.5% Crystal Violet in 25% MeOH/ 75% ddH2O) for 10 minutes. Wells were rinsed with ddH2O.
Results
BIRC5 shRNA induces apoptosis in neuroblastoma cell lines
We first validated BIRC5 as a drug target by silencing the expression using shRNA 1b) .
In addition to classical cell lines, we tested the sensitivity of 4 newly isolated TIClines to YM155. These cells were isolated directly from patient tumor or bone marrow material and maintained in neural stem cell specific medium. These TIC lines also showed sensitivity to YM155 in the low nM range (table 1) .
YM155 causes apoptosis by specific silencing of BIRC5
To evaluate the phenotype after treatment with YM155, we performed Western blot analysis. SKNAS and IMR32 showed dose-dependent BIRC5 silencing, PARP cleavage occurred at 50 nM for SKNAS and 10 nM for IMR32 (fig 2b) . Student T-test after FDR correction). ABCB1 is an outlier as revealed from the volcano-plot of all genes, indicating its significance (fig 3a) . Cell lines with a high ABCB1 expression were resistant to YM155, whereas fig 3a) . Also, children with a tumor with low ABCB1 expression have a poor prognosis according to the Kaplan Meier curve (p < 0.02 after Bonferroni correction) (suppl fig 3b) . This suggests that patients with a poor prognosis are likely to be sensitive to YM155. In addition, we investigated if BIRC5 could be a predictor for sensitivity. However, we did not find a correlation between the IC50 to YM155 and BIRC5 expression in our cell line panel (suppl fig 3c) and BIRC5 can therefore not be used as a predictor for sensitivity in neuroblastoma patients. This also holds true if we exclude the cell lines with high ABCB1 expression (data not shown).
Discussion
We conclude that 14 out of 23 neuroblastoma cell lines are sensitive to YM155 in the low nM range. Most small molecule compounds used in anticancer treatment are known to inhibit a variety of genes. The lack of specificity is an important cause of the severe side effects of these compounds and it is well established that blocking a single target with high potency minimizes the side effects. 32 YM155 was picked up by a screen that was designed to select compounds in a chemical compound library efficiently inhibiting the BIRC5 promoter. 21 This resulted in a highly effective BIRC5 suppressant as was validated in our experiments. We were able to rescue YM155 induced apoptosis by BIRC5 over-expression, which suggests that YM155 is a highly specific BIRC5 suppressant. These findings establish YM155 as an interesting compound for treatment of neuroblastoma patients.
Most interestingly, also the 4 TIC lines we tested were shown to be very sensitive to organ transplantation. It is also an active inhibitor of ABCB1; however for this use high concentrations were needed and found to be toxic in combination treatment presumably because cyclosporine induced sensitization of the bone marrow to chemo therapy. 27, 34 Currently, new inhibitors of ABC transporters are in clinical development, such as PSC833, V-104, tarquidar and ONT-093. [26] [27] [28] After clinical implementation these compounds could be combined with YM155.
Still, targeted ABCB1 inhibition is currently not possible in a clinical setting. The over-expression of ABCB1 in neuroblastoma however can be used as a selection biomarker. BIRC5 is over-expressed in almost all high risk neuroblastoma and in principle serves as drug target in these patients. As high ABCB1 expression prevents effective targeting, we propose to select ABCB1 negative patients for clinical testing of YM155. Most interestingly, this group of patients tends to have a very poor prognosis and new therapeutic options are urgently needed in this specific subgroup.
Before YM155 can be used in a Phase I/II clinical trial in neuroblastoma patients, the compound needs to be validated in a neuroblastoma mouse model. New compounds will only be used in neuroblastoma patients in combination with the currently used cytostatics. Therefore these interactions need to be evaluated. The knowledge that mitotic catastrophe is involved in the apoptotic response after BIRC5 knockdown can also guide compound combination strategies. 11 Simultaneous inhibition of other genes in the same signal transduction pathway could lead to additional or synergistic effects. For example AURKB inhibitors could potentially enhance the effect of BIRC5 inhibition as they both are part of the chromosomal passenger complex. Mitotic catastrophe results in an apoptotic response via mitochondrial release of proapoptotic proteins. Sensitization of this downstream signal transduction pathway by BCL2 inhibitors or SMAC mimetics might lead to synergism with a BIRC5 inhibitor.
Based on in vivo experiments and on knowledge about the efficacy of YM155 combined with other drugs, a Phase I/II clinical trial can be designed.
